Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
5.57
+0.51 (10.08%)
May 29, 2026, 1:27 PM EDT - Market open
Immuneering Employees
Immuneering had 53 employees as of December 31, 2025. The number of employees decreased by 13 or -19.70% compared to the previous year.
Employees
53
Change
-13
Growth
-19.70%
Revenue / Employee
n/a
Profits / Employee
-$1,027,163
Market Cap
360.36M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 53 | -1 | -1.85% |
| Sep 30, 2025 | 54 | -12 | -18.18% |
| Jun 30, 2025 | 54 | -12 | -18.18% |
| Mar 31, 2025 | 54 | -11 | -16.92% |
| Sep 30, 2024 | 66 | -1 | -1.49% |
| Jun 30, 2024 | 66 | 0 | - |
| Mar 31, 2024 | 65 | -3 | -4.41% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Sep 30, 2023 | 67 | -7 | -9.46% |
| Jun 30, 2023 | 66 | -8 | -10.81% |
| Mar 31, 2023 | 68 | 0 | - |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Sep 30, 2022 | 74 | 38 | 105.56% |
| Jun 30, 2022 | 74 | 40 | 117.65% |
| Mar 31, 2022 | 68 | 36 | 112.50% |
| Dec 31, 2021 | 64 | 38 | 146.15% |
| Sep 30, 2021 | 36 | 10 | 38.46% |
| Jun 30, 2021 | 34 | - | - |
| Mar 31, 2021 | 32 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| REGENXBIO | 371 |
| Rocket Pharmaceuticals | 202 |
| Nautilus Biotechnology | 127 |
| Invivyd | 122 |
| Neumora Therapeutics | 96 |
| Editas Medicine | 87 |
| Rezolute | 68 |
| Atea Pharmaceuticals | 55 |
IMRX News
- 7 days ago - Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy - GlobeNewsWire
- 14 days ago - Immuneering reports Q1 EPS (21c), consensus (25c) - TheFly
- 14 days ago - Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 14 days ago - Immuneering Earnings release: Q1 2026 - Filings
- 14 days ago - Immuneering Quarterly report: Q1 2026 - Filings
- 5 weeks ago - Immuneering announces updated data from Phase 2a trial for atebimetinib - TheFly
- 5 weeks ago - Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting - GlobeNewsWire
- 5 weeks ago - Immuneering announces presentation of new genetic data at 2026 AACR - TheFly